ClinicalTrials.gg
RecruitingNCT07442513Updated Mar 2, 2026

Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT

A Phase 3 interventional study of etamsylate and Placebo in Hematopoietic Stem Cell Transplantation and Thrombocytopenia, sponsored by First Affiliated Hospital of Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by First Affiliated Hospital of Zhejiang University · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
404
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 108 studies in Thrombocytopenia with a site in China — 42 open to participants now, 45 under way, 10 of them phase 3. Thrombocytopenia · China.

Planned enrollment
6th of 96
404 · median 82
Started
2025
with 17 others
Phase 3
20 of 108
4 open now
Primary completion
2027-10
later than 33 of 44 live
Registered
98th of 108
by date

Among the 108 studies in Thrombocytopenia with a site in China, this one is the 6th largest by planned enrollment of the 96 interventional ones that give a count, is one of 18 that started in 2025, is one of 20 in phase 3, reaches primary completion later than 33 of the 44 other live ones, and was the 98th registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

42 of the 108 studies in Thrombocytopenia with a site in China are open now. Recruiting first, the newest first:

36 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Thrombocytopenia with a site in China, or all of them as a file.
02

Study summary

This study employs a prospective, randomized, double-blind, placebo-controlled design. It aims to compare the efficacy of etamsylate versus placebo in preventing bleeding complications in patients with thrombocytopenia following hematopoietic stem cell transplantation.

Read the detailed description

This study employs a prospective, randomized, double-blind, placebo-controlled design. It aims to compare the efficacy of etamsylate versus placebo in preventing bleeding complications in patients with thrombocytopenia following hematopoietic stem cell transplantation. The primary endpoint is the incidence of death or bleeding events (WHO grade ≥2) within 30 days. Secondary endpoints focus on the safety profile of etamsylate versus placebo.

03

Conditions studied

  • Hematopoietic Stem Cell Transplantation
  • Thrombocytopenia

Browse trials for

Keywords

  • etamsylate
  • Hematopoietic Stem Cell Transplantation recipients
  • thrombocytopenia
  • bleeding events
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 70 years (inclusive), regardless of gender;
  2. Patients diagnosed with a hematological disease requiring hematopoietic stem cell transplantation;
  3. Expected count ≤ 10 x 10⁹/L persisting for 5 days or more;
  4. Normal coagulation function;
  5. Adequate organ function: (AST) and Alanine Aminotransferase (ALT) ≤ 3 times the (ULN), Total ≤ 2 x ULN; Serum Creatinine ≤ 2 x ULN; ≥ 50 mL/min (calculated using the Cockcroft-Gault formula); (LVEF) ≥ 50% as measured by Echocardiography (ECHO);
  6. Voluntary provision of signed , with the ability to understand and comply with all study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of acute promyelocytic leukemia confirmed according to WHO diagnostic criteria;
  2. Pregnant or breastfeeding women, and women of unwilling to use effective ;
  3. Presence of active bleeding or infection;
  4. History of diagnosed primary immune thrombocytopenia or hemolytic uremic syndrome;
  5. Patients with known hereditary or acquired hemorrhagic disorders;
  6. Patients receiving anticoagulant or antiplatelet therapy;
  7. Patients with severe cardiac insufficiency ( [EF] \< 60%); or severe arrhythmias: history of prolongation (male > 450 ms; female > 470 ms), ventricular tachycardia, atrial fibrillation, second-degree heart block; myocardial infarction within 1 year prior to enrollment; or symptomatic coronary artery disease requiring medication; patients with severe liver impairment (liver function indices [, ] > 3 times the [ULN]);
  8. Patients with severe pulmonary insufficiency (obstructive and/or restrictive ventilatory defects);
  9. Patients with severe renal insufficiency (renal function index [Cr] > 2 times ULN); or 24-hour urinary rate (Ccr) \< 50 ml/min;
  10. Patients with mental disorders or other conditions preventing provision of and compliance with study treatment and procedural requirements;
  11. Other reasons deemed by the investigator to make the patient ineligible for inclusion.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
404 participants (estimated)

Study arms

  • Experimental
    etamsylate

    Etamsylate Injection: Administer by intravenous infusion, diluted with 100ml of 0.9% Sodium Chloride Injection, twice daily.

    Drug: etamsylate

  • Placebo comparator
    placebo

    0.9% Sodium Chloride Injection, 100 ml, twice daily, intravenous drip

    Drug: Placebo

Interventions

  • DrugEthamsylateStudies of EthamsylateEthamsylate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    etamsylate Injection, administer by intravenous infusion, diluted with 100ml of 0.9% Sodium Chloride Injection, twice daily.

  • DrugPlacebo

    0.9% Sodium Chloride Injection, 100 ml, twice daily, intravenous drip

06

What researchers measure

Primary outcomes

  1. WHO grade 2 or higher bleeding events or death.

    The incidence of WHO grade 2 or higher bleeding events or death within 30 days of medication administration. Etamsylate will be considered effective compared to placebo when the incidence in the experimental group is 14.2% lower than that in the placebo group.

    Time frame: 30 days

Secondary outcomes

  1. The number of days without WHO grade 2 or higher bleeding events

    The number of days without WHO grade 2 or higher bleeding events within 30 days of medication administration. Etamsylate will be considered effective compared to placebo when the number of days without WHO grade 2 or higher bleeding events is 2 days more in the experimental group than in the placebo group.

    Time frame: 30 days

  2. The number of platelet transfusions

    Time frame: The number of platelet transfusions within 30 days of medication administration. Etamsylate will be considered effective compared to placebo when the number of platelet transfusions in the experimental group is 2.5 fewer than in the placebo group.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Oct 2027, 22 months after the start.

Of 29 phase 3 interventional studies under Thrombocytopenia, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 45. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 2, 2026
StartActual
Dec 16, 2025
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 31, 2027
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07442513
Responsible party
Yi Luo (Professor, First Affiliated Hospital of Zhejiang University) — Principal investigator
First posted
Mar 2, 2026
Start date
Dec 16, 2025
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Mar 2, 2026

Study contacts

Yi Luo
Contact
luoyijr@zju.edu.com
86-13666609126
Luxin Yang
Contact
yangluxin2016@163.com
86-13588756650
Yi Luo
principal investigator · The First Affiliated Hospital, College of Medicine, Zhejiang University Principal Investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ethamsylate

Start the discussion